Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > COMMENTARY
COMMENTARY
- Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
January 18, 2016
- Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
January 12, 2016
- High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
November 27, 2015
- Sakigake Designation System to Link Regulatory and Drug Pricing Systems; Could Result in Tougher Scrutiny for Designated Products
November 6, 2015
- Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key
October 13, 2015
- Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System
September 24, 2015
- How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
August 18, 2015
- Leaner Sales Forces? Lower Profits? Drug Makers Face Tough Decision in 80% Generic Era
August 14, 2015
- PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018
August 12, 2015
- Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground
July 21, 2015
- Viable Third-Party Review System Required for Drug Makers’ Advertisements
July 7, 2015
- Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
- Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
June 15, 2015
- Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
May 26, 2015
- 1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
May 8, 2015
- Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
April 27, 2015
- Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
April 17, 2015
- Patient Subsidy System Expanded for Intractable Diseases, What about Incentives for Drug Makers?
April 7, 2015
- Abe Pledges Biosimilar Promotion, but Doctor Misconception and Lack of Incentives Remain as Challenges
March 30, 2015
- SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
March 17, 2015
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…